The CDER Medical Policy Council’s review of “breakthrough therapy” designation requests for specific products and indications marks a departure from the council’s charge to take a big picture approach to addressing broader, non-product-specific policy challenges.
Nevertheless, the task of reviewing the growing number of breakthrough requests has been handed to the council to ensure consistency...